First National Bank of Mount Dora Trust Investment Services boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.6% in the second quarter, HoldingsChannel reports. The firm owned 132,530 shares of the biopharmaceutical company’s stock after acquiring an additional 773 shares during the period. Pfizer makes up 2.4% of First National Bank of Mount Dora Trust Investment Services’ portfolio, making the stock its 9th biggest position. First National Bank of Mount Dora Trust Investment Services’ holdings in Pfizer were worth $6,949,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Aureus Asset Management LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $221,000. Nuveen Asset Management LLC increased its stake in shares of Pfizer by 18.0% in the 4th quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock valued at $1,658,518,000 after buying an additional 4,278,167 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Pfizer in the 4th quarter valued at $237,000. Odey Asset Management Group Ltd increased its stake in shares of Pfizer by 85.7% in the 4th quarter. Odey Asset Management Group Ltd now owns 130,000 shares of the biopharmaceutical company’s stock valued at $7,677,000 after buying an additional 60,000 shares during the period. Finally, Banco de Sabadell S.A increased its stake in shares of Pfizer by 16.7% in the 4th quarter. Banco de Sabadell S.A now owns 47,358 shares of the biopharmaceutical company’s stock valued at $2,797,000 after buying an additional 6,793 shares during the period. 67.90% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have recently commented on PFE. The Goldman Sachs Group set a $50.00 target price on Pfizer in a research note on Thursday, September 1st. Barclays set a $50.00 price objective on Pfizer in a research note on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, June 28th. Berenberg Bank set a $44.00 price objective on Pfizer in a research note on Wednesday, September 14th. Finally, SVB Leerink decreased their price objective on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research note on Friday, July 29th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company’s quarterly revenue was up 46.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 earnings per share. Equities analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.